Pharmacology and Systems Therapeutics

The Dorothy H. and Lewis Rosenstiel Department of Pharmacology and Systems Therapeutics focuses on the biological mechanisms underlying complex physiologies and pathophysiologies and translating biological knowledge into new therapeutics. We are a basic science department within the Icahn School of Medicine at Mount Sinai.

We pursue a multifaceted mission of research, research training at the predoctoral and postdoctoral levels, and medical school teaching. We conduct predoctoral training in pharmacological sciences under the auspices of the Graduate School of Biomedical Sciences.

Our Focus

We study biological processes at the molecular, cellular, tissue, and organismal level in order to understand how these processes function and how we can modulate them for therapeutic purposes. Studies often involve analysis of interactions of exogenous and endogenous substances with biological systems and the development of new therapeutics based on our understanding of cellular and molecular interactions.

Systems pharmacology and therapeutics represents a continuum of thought and research in understanding the origins and mechanisms underlying complex diseases and how we can treat them.

Our Programs and Training

Our faculty members participate in a number of predoctoral and postdoctoral training programs funded by the National Institutes of Health (NIH):

Our Research

Our research laboratories are pioneering new discoveries in three broad areas:

  • Biochemistry and regulatory biology
  • Applied mathematics and systems biology
  • Physiology and drug development

Our department is home to a National Institute of General Medical Sciences-funded National Center for Systems Biology. The Systems Biology Center New York (SBCNY) brings together our faculty with a highly collaborative multi-disciplinary group of researchers, both basic and clinical, and educators from several universities in the New York area to develop the field of systems pharmacology.

Our faculty leads three research centers primarily funded through the NIH Common Fund, which supports high-impact leading-edge research across the NIH.